Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Haemostaseology].

K Schrör1

  • 1Institut für Pharmakologie und Klinische Pharmakologie, Universitätsklinikum Düsseldorf, Germany. kschroer@uni-duesseldorf.de

Der Internist
|July 1, 2005
PubMed
Summary

New anticoagulants and antiplatelet drugs offer improved antithrombotic potential. These novel agents, including direct thrombin inhibitors and clopidogrel, show promise but require further risk-benefit assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Importance of acetylsalicylic acid in primary prevention : ASCEND, ARRIVE and ASPREE as well as a meta-analysis by Rothwell et al.]

Der Internist·2019
Same author

[Cardiovascular safety of celecoxib : Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION)].

Der Internist·2017
Same author

Why we should not skip aspirin in cardiovascular prevention.

Hamostaseologie·2015
Same author

Inhibition of antiplatelet effects of aspirin by nonopioid analgesics.

Clinical pharmacology and therapeutics·2015
Same author

[Aspirin and venous thromboses].

Der Internist·2015
Same author

[Perioperative aspirin treatment in patients undergoing surgery: Perioperative Ischemic Evaluation 2 (POISE-2)].

Der Internist·2014

Area of Science:

  • Pharmacological research
  • Drug development

Context:

  • Antithrombotics are crucial for managing thrombotic disorders.
  • Heparins and coumarins are traditional antithrombotic agents.

Purpose:

  • To review the advancements in the design and development of novel antithrombotic agents.
  • To highlight new anticoagulants and antiplatelet drugs.

Summary:

  • Development of new anticoagulants, such as hirudin analogs and low-molecular-weight inhibitors of thrombin and factor Xa, offers direct inhibition of thrombin.
  • Orally active anticoagulants are in clinical trials and may replace coumarins for long-term use.
  • Clopidogrel represents a significant advancement in antiplatelet therapy, with synergistic effects when combined with aspirin and GP-IIb/IIIa antagonists.

Impact:

  • Novel antithrombotics demonstrate enhanced antithrombotic potential with potentially reduced bleeding tendencies.
  • These agents may offer safer and more effective alternatives to existing therapies.
  • Further evaluation of the individual risk-benefit ratio is necessary, especially for anticoagulants.

Related Experiment Videos